4298-14-0

Basic information

• Product Name: BISDESETHYL CHLOROQUINE
• Synonyms: Bisdeethylchloroquine;Didesethyl Chloroquine Hydrochloride;N,N-Dideethylchloroquine;N4-(7-Chloro-4-quinolinyl)-1,4-pentanediamine Hydrochloride;4-[(4-Amino-1-methylbutyl)amino]-7-chloroquinoline;Didesethyl Chloroquine;N4-(7-Chloro-4-quinolinyl)-1,4-pentanediamine;BDCQ
• CAS NO: 4298-14-0
• Molecular Formula: C14H18ClN3
• Molecular Weight: 263.77
• Product Categories: Various Metabolites and Impurities;Amines;Heterocycles;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Metabolite
• Mol File: 4298-14-0.mol

Chemical Properties

• Melting Point: 139-141°C
• Boiling Point: 441.4°C at 760 mmHg
• Flash Point: 220.8°C
• Appearance: /
• Density: 1.208g/cm³
• Vapor Pressure: 5.44E-08mmHg at 25°C
• Refractive Index: 1.64
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 10.37±0.10(Predicted)
• CAS DataBase Reference: BISDESETHYL CHLOROQUINE(CAS DataBase Reference)
• NIST Chemistry Reference: BISDESETHYL CHLOROQUINE(4298-14-0)
• EPA Substance Registry System: BISDESETHYL CHLOROQUINE(4298-14-0)

Safety Data

• Hazardous Substances Data: 4298-14-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
BISDESETHYL CHLOROQUINE is used as a research compound for exploring its potential therapeutic effects against COVID-19. As a metabolite of Chloroquine, it has been investigated for its possible antiviral properties and its ability to mitigate the severity of the disease caused by the SARS-CoV-2 virus.
Used in COVID-19-related Research:
In the context of COVID-19, BISDESETHYL CHLOROQUINE is used as a subject of study to understand its role in combating the virus. Researchers are examining its efficacy in treating patients infected with COVID-19, as well as its potential side effects and safety profile. The goal is to determine if it can be a viable treatment option for those affected by the virus.
Used in Drug Development:
BISDESETHYL CHLOROQUINE is also used as a starting point for the development of new drugs and therapies. Its chemical properties and metabolite status make it a valuable compound for researchers to modify and optimize, potentially leading to the creation of more effective treatments for various diseases, including COVID-19.

InChI:InChI=1/C14H18ClN3/c1-10(3-2-7-16)18-13-6-8-17-14-9-11(15)4-5-12(13)14/h4-6,8-10H,2-3,7,16H2,1H3,(H,17,18)

Upstream product

• 54-05-7 Chloroquine 
• 701255-53-0 tert-butyl (4-aminopentyl)carbamate 
• 591-77-5 1-methyl-1,4-butanediamine 
• 99595-69-4 1,4-bis(azido)pentane 
• 626-87-9 1,4-dibromopentane 

Relevant articles and documents

Bacterial Biosynthetic P450 Enzyme PikCD50N: A Potential Biocatalyst for the Preparation of Human Drug Metabolites

Human drug metabolites (HDMs) are important chemicals widely used in drug-related studies. However, acquiring these enzyme-derived and regio-/stereo-selectively modified compounds through chemical approaches is complicated. PikC is a biosynthetic P450 enz

Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?

The syntheses and antiplasmodial activities of various substituted aminoquinolines coupled to an adamantane carrier are described. The compounds exhibited pronounced in vitro and in vivo activity against Plasmodium berghei in the Thompson test. Tethering a fluorine atom to the aminoquinoline C(3) position afforded fluoroaminoquinolines that act as intrahepatocytic parasite inhibitors, with compound 25 having an IC50 = 0.31 μM and reducing the liver load in mice by up to 92% at 80 mg/kg dose. Screening our peroxides as inhibitors of liver stage infection revealed that the tetraoxane pharmacophore itself is also an excellent liver stage P. berghei inhibitor (78: IC50 = 0.33 μM). Up to 91% reduction of the parasite liver load in mice was achieved at 100 mg/kg. Examination of tetraoxane 78 against the transgenic 3D7 strain expressing luciferase under a gametocyte-specific promoter revealed its activity against stage IV-V Plasmodium falciparum gametocytes (IC50 = 1.16 ± 0.37 μM). To the best of our knowledge, compounds 25 and 78 are the first examples of either an 4-aminoquinoline or a tetraoxane liver stage inhibitors.

NEW OLIGOMERIC CONJUGATES LIABLE TO TRANSFER BIOLOGICAL MOLECULES INTO CELLS

The invention relates to a positively charged oligomeric conjugate, containing an oligomer with a polymerization degree (PD) from 5 to 50, preferably 10 to 40 and more preferably 20, formed from monomeric components having free NH3 in a number equal to or higher than 50 % of the polymerization degree. In particular, the invention provides new oligomeric conjugates of histidylated oligolysine liable to allow the transfer of oligonucleotides, peptides and oligosides into cells.